| Authors: |
Aboshi M; VLP Therapeutics Japan, Inc., 1-16-4 Nishi-Shinbashi, Minato-ku, Tokyo 105-0003, Japan., Matsuda K; VLP Therapeutics, Inc., Gaithersburg, MD 20878, USA., Kawakami D; VLP Therapeutics Japan, Inc., 1-16-4 Nishi-Shinbashi, Minato-ku, Tokyo 105-0003, Japan., Kono K; VLP Therapeutics Japan, Inc., 1-16-4 Nishi-Shinbashi, Minato-ku, Tokyo 105-0003, Japan., Kazami Y; VLP Therapeutics Japan, Inc., 1-16-4 Nishi-Shinbashi, Minato-ku, Tokyo 105-0003, Japan., Sekida T; VLP Therapeutics Japan, Inc., 1-16-4 Nishi-Shinbashi, Minato-ku, Tokyo 105-0003, Japan., Komori M; VLP Therapeutics, Inc., Gaithersburg, MD 20878, USA., Morey AL; VLP Therapeutics, Inc., Gaithersburg, MD 20878, USA., Suga S; National Hospital Organization, Mie National Hospital, Tsu, Mie 514-0125, Japan., Smith JF; VLP Therapeutics, Inc., Gaithersburg, MD 20878, USA., Fukuhara T; Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Hokkaido 060-0815, Japan.; Laboratory of Virus Control, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka 565-0871, Japan., Iwatani Y; Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Aichi 460-0001, Japan.; Division of Basic Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466-8550, Japan., Yamamoto T; Laboratory of Precision Immunology, Center for Intractable Diseases and ImmunoGenomics, National Institutes of Biomedical Innovation, Health and Nutrition, Ibaraki, Osaka 567-0085, Japan., Sato N; VLP Therapeutics Japan, Inc., 1-16-4 Nishi-Shinbashi, Minato-ku, Tokyo 105-0003, Japan., Akahata W; VLP Therapeutics Japan, Inc., 1-16-4 Nishi-Shinbashi, Minato-ku, Tokyo 105-0003, Japan. |
